Wholesaler Forward-Buying Is Back, J&J Says; Rx Price Increases Pick Up
Executive Summary
Johnson & Johnson is seeing an upward trend in forward-buying by wholesalers, CFO Robert Darretta told analysts Jan. 23 in New York City.
You may also be interested in...
AstraZeneca Nexium Data Shows 47% Of Scripts Are First-Time PPI Users
Nexium sales data from the U.K. and Germany shows that 47% of prescriptions are for patients new to proton pump inhibitors, AstraZeneca CEO Tom McKillop, PhD, reported at the company's year-end earnings conference in London Feb. 8.
AstraZeneca Nexium Data Shows 47% Of Scripts Are First-Time PPI Users
Nexium sales data from the U.K. and Germany shows that 47% of prescriptions are for patients new to proton pump inhibitors, AstraZeneca CEO Tom McKillop, PhD, reported at the company's year-end earnings conference in London Feb. 8.
J&J Remicade Sales Reach $370 Mil.; Procrit To Pass $3 Bil. In '01, Firm Says
J&J/Centocor's Remicade may help Johnson & Johnson move past Amgen to claim the title of the largest biotechnology company in the world in 2001.